In a surprising turn, Anne Wojcicki's nonprofit, TTAM Research Institute, has acquired 23andMe for $305 million after its bankruptcy. This acquisition addresses concerns about genetic data privacy while aiming to uphold the company's mission.
Anne Wojcicki's nonprofit has won the bid to buy 23andMe, raising critical questions about the future of genetic data privacy. Experts warn that sensitive DNA information could be at risk.
In a groundbreaking move, 27 states and D.C. have filed a lawsuit to prevent 23andMe from selling customer genetic data without consent. This legal battle raises significant privacy concerns for users.
Hims & Hers Health is set to acquire European telehealth platform Zava, aiming to expand its services across Europe. The deal promises to add 1.3 million customers and enhance access to affordable medications in Ireland, France, and Germany.
In a bold move, President Trump is set to sign an executive order mandating the U.S. health department to negotiate lower drug prices with pharmaceutical companies. This could drastically change healthcare costs for millions of Americans.
In a surprising move, China has exempted some U.S. imports from steep tariffs, hinting that the trade war may be easing. However, Beijing contradicts claims of ongoing negotiations with Washington.
President Trump announces significant tariffs on pharmaceutical imports to revive U.S. manufacturing. Will this bold move shake the global drug market and impact upcoming midterms?
In a dramatic response to escalating US trade tariffs, New Zealand cuts interest rates, raising concerns about a global recession. Markets across Asia tumble as Trump's new tariffs take effect. Discover the potential fallout and what it means for economies worldwide.
In a surprising turn, Indian drugmakers' shares jumped 5% following the U.S. exempting pharmaceuticals from new tariffs. This decision could significantly boost India's pharma exports, which reached $9 billion last year.
President Trump is set to announce new tariffs on automobiles and pharmaceuticals soon, adding to his ongoing trade war strategy that includes steel and aluminum duties. This move signals a broader effort to reshape U.S. trade policies as April 2 approaches.
